Reumatologia Clinica最新文献

{"title":"Carteles Generales (CG001-CG186)","authors":"","doi":"10.1016/S1699-258X(25)00064-6","DOIUrl":"10.1016/S1699-258X(25)00064-6","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 ","pages":"Pages S224-S372"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seguridad de terapias biológicas y sintéticas dirigidas en pacientes con enfermedades inmunomediadas: datos del registro BIOBADAGUAY","authors":"Paloma de Abreu ,&nbsp;Sonia Cabrera ,&nbsp;Darwin Cordovilla ,&nbsp;Lourdes Román ,&nbsp;Cristina Brunengo ,&nbsp;Patricia Melgarejo ,&nbsp;Macarena Soto ,&nbsp;Vannia Valinotti ,&nbsp;Angelica Amarilla ,&nbsp;Belem Acevedo ,&nbsp;Alexis Pineda ,&nbsp;Evelyn Leiva ,&nbsp;Paola Pusineri ,&nbsp;Sandra Consani ,&nbsp;Mariela Zarza ,&nbsp;Clyde Parodi ,&nbsp;Zoilo Morel ,&nbsp;Roger Rolón ,&nbsp;Paola Jara ,&nbsp;Raquel Aranda ,&nbsp;Gabriela Ávila","doi":"10.1016/j.reuma.2024.09.008","DOIUrl":"10.1016/j.reuma.2024.09.008","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).</div></div><div><h3>Methods</h3><div>BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at <span><span>https://biobadaguay.ser.es</span><svg><path></path></svg></span>. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).</div></div><div><h3>Results</h3><div>1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.</div></div><div><h3>Conclusions</h3><div>This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 101798"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfermedades reumatológicas en pacientes con hepatitis autoinmune en un hospital de cuarto nivel de Bogotá entre el 2013 al 2023","authors":"Juan Sebastián Almánzar Cortés ,&nbsp;Cathalina Vergara Cabra ,&nbsp;María Paula Uchima-Vera ,&nbsp;Gerardo Quintana ,&nbsp;Fernando Sierra","doi":"10.1016/j.reuma.2024.501812","DOIUrl":"10.1016/j.reuma.2024.501812","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with low prevalence worldwide. The coexistence of this entity with rheumatic diseases has been evaluated in multiple studies and is highly variable. The objective of this study is to identify the frequency of coexistence of rheumatic diseases and autoimmune hepatitis in adults who have been treated for 10<!--> <!-->years in a fourth-level hospital in Bogota, Colombia.</div></div><div><h3>Materials and methods</h3><div>Analytical, observational, cross-sectional study in a single center that included patients over 18<!--> <!-->years of age of both sexes with a diagnosis of AIH by simplified score ≥<!--> <!-->7<!--> <!-->points, with a medical history registered at the Fundacion Santa Fe de Bogota in Bogota, Colombia, between January 2013 and December 2023.</div></div><div><h3>Results</h3><div>A total of 66 patients met inclusion criteria. 36.4% of patients had a concomitant autoimmune disease, with Sjögren's syndrome, systemic lupus erythematosus and autoimmune thyroid disease being the most prevalent.</div></div><div><h3>Conclusion</h3><div>The frequency of coexistence of autoimmune hepatitis with rheumatic diseases in adult patients is 36.4% for the cohort studied, which is within the range of what has already been reported globally, where a prevalence of 14 to 44% has been described.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 501812"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discusión de Casos Clínicos (DCC001-DCC029)","authors":"","doi":"10.1016/S1699-258X(25)00062-2","DOIUrl":"10.1016/S1699-258X(25)00062-2","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 ","pages":"Pages S173-S197"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perforación ileal terminal no traumática en un paciente con reumatismo palindrómico refractario tratado con sarilumab: reporte de caso","authors":"Anastasia Mocritcaia ,&nbsp;Rocío García-Pérez ,&nbsp;Beatriz Frade ,&nbsp;Raimon Sanmartí","doi":"10.1016/j.reuma.2024.501811","DOIUrl":"10.1016/j.reuma.2024.501811","url":null,"abstract":"<div><div>Intestinal perforation, a rare complication of interleukin (IL)-6 therapy for immune-mediated diseases (mainly rheumatoid arthritis), typically manifests in the lower gastrointestinal tract, often in association with prior history of diverticulitis. Patients may present with acute abdominal pain and suspicion for this complication should remain high even in the absence of elevated C-reactive protein. We describe a 69-year-old female patient with a history of resistant seropositive palindromic rheumatism treated with sarilumab who developed a nontraumatic terminal ileal perforation.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 501811"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling","authors":"Akhil Akhil ,&nbsp;Rohit Bansal ,&nbsp;Jyotsana Kaushal ,&nbsp;Aman Sharma ,&nbsp;Archana Bhatnagar","doi":"10.1016/j.reuma.2024.10.006","DOIUrl":"10.1016/j.reuma.2024.10.006","url":null,"abstract":"<div><h3>Objectives</h3><div>Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.</div></div><div><h3>Methodology</h3><div>Age and sex matched healthy donors and patients (<em>n</em> <!-->=<!--> <!-->38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.</div></div><div><h3>Results</h3><div>A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.</div></div><div><h3>Conclusion</h3><div>This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 1","pages":"Article 101805"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143304892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Análisis bibliométrico de la producción científica de los servicios de reumatología en España en el período 2013-2022","authors":"Daniel Seoane-Mato ,&nbsp;Fernando Sánchez-Alonso ,&nbsp;Mercedes Guerra-Rodríguez ,&nbsp;Enrique González-Dávila ,&nbsp;Federico Díaz-González","doi":"10.1016/j.reuma.2024.10.008","DOIUrl":"10.1016/j.reuma.2024.10.008","url":null,"abstract":"<div><h3>Background and objective</h3><div>Bibliometric studies of scientific production in Spanish Rheumatology are scarce. The aim of this study was to analyze the bibliographic production of rheumatology services in Spain over the period 2013-2022.</div></div><div><h3>Materials and methods</h3><div>Original articles and reviews with the affiliation of the first or corresponding author to a Spanish rheumatology service/department/section/unit were identified in the Web of Science Core Collection and Scopus databases. Keywords and titles were used to classify articles by field (clinical, epidemiological or basic) and pathology. International collaborations and collaborations between Autonomous Communities (AC) were identified. Quantitative bibliometric indicators were obtained (number of articles published per year, pathology and AC) and impact indicators were obtained (based on the number of citations per article). The H-index was also calculated.</div></div><div><h3>Results</h3><div>The total number of publications was 2321, with an annual growth rate of 4.1% in the period analyzed. In 14.1% of the articles there were international collaborations, mainly with the United States and the United Kingdom, while between ACs the most numerous were between Madrid and Catalonia. The pathologies with the highest H-index were rheumatoid arthritis (RA), spondyloarthropathies (SpA), osteoarthritis and vasculitis (34, 32, 28 and 26, respectively). The H-index for the Spanish rheumatology services as a whole was 69.</div></div><div><h3>Discussion and conclusions</h3><div>The scientific production of rheumatology services/departments/sections/units in our country increased between 2013 and 2022. By pathology, the scientific production in RA and SpA stands out.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 1","pages":"Article 101807"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143304895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efecto de la liraglutida en pacientes con artritis psoriásica y obesidad","authors":"Joana Nicolau ,&nbsp;Antoni Nadal ,&nbsp;Inmaculada Ros ,&nbsp;Lluís Masmiquel","doi":"10.1016/j.reuma.2024.501809","DOIUrl":"10.1016/j.reuma.2024.501809","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 1","pages":"Article 501809"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143304896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mepolizumab efficacy and safety in patients with eosinophilic granulomatosis with polyangiitis in real practice: Data from a Spanish retrospective multicentric register from Rheumatology departments","authors":"Francisco Rubiño Juárez ,&nbsp;Rosario García de Vicuña ,&nbsp;Esther Vicente ,&nbsp;Esther Rodríguez Almaraz ,&nbsp;Nuria Lozano Rivas ,&nbsp;Mercedes Freire González ,&nbsp;Alejandro Olivé Marqués ,&nbsp;Annika Nack ,&nbsp;Javier Narváez García ,&nbsp;Patricia Moya Alvarado ,&nbsp;Esther Uriarte Itzazelaia ,&nbsp;Nerea Alcorta Lorenzo ,&nbsp;José Luis Marenco de la Fuente ,&nbsp;Consuelo Ramos ,&nbsp;Valvanera Pinillos Aransay ,&nbsp;Ricardo Blanco Alonso ,&nbsp;Fabricio Benavides Villanueva ,&nbsp;María Paz Martínez Vidal ,&nbsp;Jesús María González Martín ,&nbsp;Íñigo Rúa-Figueroa","doi":"10.1016/j.reuma.2024.10.007","DOIUrl":"10.1016/j.reuma.2024.10.007","url":null,"abstract":"<div><h3>Objectives</h3><div>Eosinophilic granulomatosis with polyangiitis (EGPA) is a type of ANCA-associated vasculitis mostly mediated by eosinophils. Mepolizumab (MPZ) reduces the absolute number of eosinophils in the peripheral blood and tissues and has proven efficacy in the maintenance of EGPA, as shown in a randomized controlled trial. The aim of this study is to describe the use of MPZ in EGPA in real clinical practice.</div></div><div><h3>Methods</h3><div>This is a descriptive, retrospective and comparative analysis of the clinical features, course, response rates, outcomes and adverse effects of patients receiving MPZ for EGPA in thirteen Spanish Rheumatology departments.</div></div><div><h3>Results</h3><div>A total of 30 EGPA patients treated with MPZ were included in the analysis. Up to 19 patients needed at least one concomitant immunosuppressant. The mean follow-up was 16 months. The use of MPZ reduced the median Birmingham Vasculitis Activity Score (BVAS), as well as the mean C-reactive protein and the levels of eosinophils. In addition, the median dose of glucocorticoids (GC) required was reduced in 79.3% of the patients and was completely suspended in 57.1%. Interestingly, the median Vasculitis Damage Index (VDI) was also calculated in 27 patients (90%), and remained stable (3 [0–12] pre-MPZ and 3 [0–12] post-MPZ). None of the patients suffered severe adverse effect, local reactions or serious infections during the treatment.</div></div><div><h3>Conclusions</h3><div>Our data on the real practice use of MPZ in EGPA suggests that this drug has good efficacy, is safe and reduces the dependence on glucocorticoids or even their complete withdrawal. Furthermore, it appears to prevent the organic damage progression associated with this disease.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 1","pages":"Article 101806"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143304893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk in patients with osteoporosis within a Rheumatology setting. Results from a Spanish survey-based multicenter study","authors":"Enrique Casado ,&nbsp;Irene Gómez-Olmedo ,&nbsp;on behalf of the VASOS Study Group","doi":"10.1016/j.reuma.2024.09.009","DOIUrl":"10.1016/j.reuma.2024.09.009","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Osteoporosis (OP) and cardiovascular diseases (CVDs) share pathophysiological mechanisms and risk factors. The severity of OP correlates with cardiovascular (CV) risk, suggesting the need for integrated clinical approaches. The VASOS study aimed to have an approach to the frequency of comorbidities, especially CVD, and cardiovascular risk factors (CVRF), in OP patients in Spain within a Rheumatology setting, assessing their possible impact on OP treatment decisions.</div></div><div><h3>Materials and methods</h3><div>Spanish survey-based multicentre study involving 62 Spanish rheumatologists, which give information from the last 10 patients. Participants were selected according to their clinical expertise and their geographical area. Questions were oriented to describe the profile of patients (OP and CVRF), and prescription habits. “Influence on treatment choice” was only accounted if the presence of one or more CVRF could affect the selection of the OP treatment.</div></div><div><h3>Results</h3><div>Data from 620 patients were collected. The patients were predominantly women (85.2%) with primary OP (73.2%). Bisphosphonates, denosumab and teriparatide were the most used treatments. Most common comorbidities included inflammatory rheumatic or autoimmune diseases, endocrinopathies and major CVD. CVRF influenced treatment choice for 82.3% of rheumatologists, who often avoided prescribing romosozumab, selective oestrogen receptor modulators (SERMs), and menopausal hormone therapy (MHT).</div></div><div><h3>Conclusions</h3><div>Most patients with OP are women with primary OP, often having CVRF. Oral bisphosphonates, denosumab, and teriparatide are the preferred treatments, avoiding MHT, SERMs, and romosozumab in patients with CVRF.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 1","pages":"Article 101799"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143304863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}